Market Overview

Merck, Bristol Myers Shares Move On Alleged FDA Alert On Keytruda

Share:
Merck, Bristol Myers Shares Move On Alleged FDA Alert On Keytruda

The U.S. Food and Drug Administration issued an alert on issues discovered in ongoing studies of Merck & Co., Inc. (NYSE: MRK)’s Keytruda Roche’s Tecentriq, according to a headline from Bloomberg. Regulators reportedly found that some patients had decreased survival.

Why It’s Important

Keytruda, which is already approved for the treatment of cancers such as melanoma, non-small cell lung cancer and Hodgkin lymphoma, is a considered a major opportunity for Merck. Updates on the drug are enough to move the stock and sway bearish experts.

A threat to Keytruda is notable for Merck, but it also carries implications for Bristol-Myers Squibb Co (NYSE: BMY), whose Opdivo competes for market share. BMO Capital Markets recently noted the drugs are “more similar than different.”

Merck shares initially fell 3 percent on the news, while Bristol Myers rose marginally.

What’s Next

The FDA has not yet published a report on the matter, but clarity on the alleged “issues” could help or hurt the rival drugmakers.

Related Links:

One Up, One Down: Morgan Stanley Flips Merck, Bristol-Myers Ratings

BMO Sees Balanced Risk-Reward In Bristol-Myers, Takes Neutral Position

Posted-In: Keytruda OpdivoNews Rumors FDA Best of Benzinga

 

Related Articles (BMY + MRK)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Skyworks Downgraded By Raymond James On Lack Of Upside Potential

4 Tech Companies Seeing High Demand For Blockchain Services